Popular terms

Dimethyl topics
Physiologic
Hydrochloric Acid
Fresnel Zone
Aberration
Ophthalmic
Liquid Crystal
Imaging System
Pharmaceutically Acceptable Salt
Pharmaceutically Acceptable Salts
Chloric Acid
Tartaric Acid
Fumaric Acid
Antagonist
Bradykinin
Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Dimethyl patents



      

This page is updated frequently with new Dimethyl-related patent applications.




Date/App# patent app List of recent Dimethyl-related patents
02/04/16
20160033681 
 Fabrication of lenses by droplet formation on a pre-heated surface patent thumbnailFabrication of lenses by droplet formation on a pre-heated surface
A lithography-free, mold-free, single-step method of fabricating high quality optical lenses by curing polydimethylsiloxane (pdms) droplets on a pre-heated smooth surface allows lenses with different focal lengths to be made by varying the droplet volume and surface temperature.. .
University Of Houston System


02/04/16
20160033522 
 Methylcitrate analysis in dried blood spots patent thumbnailMethylcitrate analysis in dried blood spots
There is provided a method of measuring methylcitrate (mca) in a sample by derivatizing the mca, for example with 4-[2-(n,n-dimethylamino)ethylaminosulfonyl]-7-(2-aminoethylamino)-2,1,3-benzoxadiazole (daabd-ae); measuring a level of the derivatized mca; and determining the level of mca from the measured level. The sample may be a dried blood spot (dbs), and the extraction and derivatization may be carried out simultaneously.
Children's Hospital Of Eastern Ontario


02/04/16
20160033389 
 Stimulus responsive polymeric system patent thumbnailStimulus responsive polymeric system
Herein, a polymer-based device capable of lifting many times its own mass was fabricated by drying a solution of the polycation poly (diallyldimethyl ammonium chloride) (pdadmac) on a surface coated with charged poly (n-isopropylacrylamide)-based microgels. Due to strong polymer-polymer and polymer-surface interactions, when the pdadmac solution dries on the microgel-modified surface, it bends.
The Governors Of The University Of Alberta


02/04/16
20160032115 
 Solvent formulations patent thumbnailSolvent formulations
The present disclosure provides, in part, solvent compositions including an acetic acid alkyl (c—c) ester (e.g., methyl acetate (ma), ethyl acetate (ea), or tert-butyl acetate (tbac)) and a carbonate ester (e.g., dimethyl carbonate, or propylene carbonate), and optionally, a benzene-containing compound. The solvent compositions may be used to replace methyl ethyl ketone (mek)..
Tbf Environmental Technology Inc.


02/04/16
20160032042 
 Process for producing flexible polyurethane foam using natural oil polyols patent thumbnailProcess for producing flexible polyurethane foam using natural oil polyols
A composition and process useful to make flexible polyurethane foams and in particular flexible molded polyurethane foams is disclosed. The usage of dipolar aprotic liquids such as dmso, dmi, sulfolane, n-methyl-acetoacetamide, n, n-dimethylacetoacetamide as well as glycols containing hydroxyl numbers oh#≦1100 as cell opening aides for 2-cyanoacetamide or other similar molecules containing active methylene or methine groups to make a polyurethane foam is also disclosed.
Air Products And Chemicals, Inc.


02/04/16
20160031867 
 An improved process for the preparation of aprepitant patent thumbnailAn improved process for the preparation of aprepitant
The present invention provides a process for the preparation of 5-[[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazole-3-one (aprepitant) comprising condensation of 2-(r)-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(s)-(4-fluorophenyl)morpholine hydrochloride salt with 2-(2-chloro-1-iminoethyl)hydrazinecarboxylic acid methyl ester to obtain the reaction mixture containing 2-[2-[(2r,3s)-2-[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]-1-iminoethyl]hydrazinecarboxylic acid methyl ester, which is in-situ cyclized in the presence of dimethylsulfoxide and a polar protic solvent at a low temperature to yield aprepitant having purity ≧99.5%.. .
Piramal Enterprises Limited


02/04/16
20160031822 
 3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) patent thumbnail3'-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
Disclosed are novel pharmaceutical compositions containing 3′-[(2z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3-carboxylic acid bis-(monoethanolamine) (eltrombopag olamine) and processes for preparing the same.. .
Novartis Ag


02/04/16
20160031791 
 Process for the production of acetic acid and dimethyl ether patent thumbnailProcess for the production of acetic acid and dimethyl ether
A process for the production of acetic acid and dimethyl ether by contacting a mixture of methanol and methyl acetate with a zeolite catalyst wherein the zeolite has a 2-dimensional channel system comprising at least one channel having a 10-membered ring and having at least 5% of its cation exchange capacity occupied by one or more alkali metal cations.. .
Bp Chemicals Limited


02/04/16
20160030478 
 Materials and methods to enhance hematopoietic stem cells engraftment procedures patent thumbnailMaterials and methods to enhance hematopoietic stem cells engraftment procedures
This disclosure is directed to the methods of enhancing hematopoietic stem cells (hspc) and progenitor cell (hspc) engraftment procedure. Treatment in vivo of a hspc donor with compounds that reduce pge2 biosynthesis or pge2 receptor antagonists alone, or in combination with other hematopoietic mobilization agents such as amd3100 and g-csf, increases the circulation of available hspcs.
Indiana University Research And Technology Corp.


02/04/16
20160030442 
 Novel compounds patent thumbnailNovel compounds
Wherein r1 is 2-indanyl, r2 is 1-methylpropyl, r3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, r4 represents methyl and r5 represents hydrogen or methyl or, r4 and r5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.. .

02/04/16
20160030395 

Substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones


Disclosed are substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compounds, pharmaceutical compositions comprising at least one such 4 substituted 5-(3,5-dimethylisoxazol-4-yl)indoline-2-one compound processes for the preparation thereof, and the use thereof for inhibiting bet family of bromodomains and for treating disorders mediated thereby, such as certain cancers.. .
Beigene, Ltd.


02/04/16
20160030366 

Compositions and methods including leelamine and arachidonyl trifluoromethyl ketone relating to treatment of cancer


The present invention relates to compositions and methods for treatment of proliferative disease. In specific aspects, the present invention relates to compositions including (1r,4as,10ar)-1,2,3,4,4a,9,10,10a-octahydro-1-,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenemethanamine (leelamine) and arachidonyl trifluoromethyl ketone (atk) in combination; methods for treatment of cancer including administration of leelamine and atk in a subject in need thereof; and particularly methods for treatment of skin cancer including administration of leelamine and atk in a subject in need thereof..
The Penn State Research Foundation


02/04/16
20160030364 

Therapeutic compositions and uses thereof


This invention provides pharmaceutical compositions comprising compounds including 5-phenylpenta-2,4-dienoic acid, 3-methyl-3-butenyl caffeic acid, 1,1-dimethylallyl caffeic acid, pinobanksin-3-acetate, tectochrysin, pinostrobin chalcone, benzyl ferulate and benzyl isoferulate. Methods of using such compositions, in particular in the treatment or prevention of gastrointestinal cancers, and the resensitisation of gastrointestinal cancers to therapy are also provided..
Manuka Health New Zealand Limited


01/28/16
20160024250 

Polymer compositions based on pxe


New polymer compositions based on poly(2,6-dimethyl-1,4-phenylene oxide) and other high-softening-temperature polymers are disclosed. These materials have a microphase domain structure that has an ionically-conductive phase and a phase with good mechanical strength and a high softening temperature.
Seeo, Inc


01/28/16
20160023976 

Process for the preparation of 3,7-dimethylnonan-1-ol


The present invention is related to a novel and improved process for the preparation of 3,7-dimethylnonan-1-ol.. .
Dsm Ip Assets B. V.


01/28/16
20160022860 

Minimizing biological lipid deposits on contact lenses


Method for minimizing the sorption of tear lipids on frequent replacement, or extended-wear, contact lenses, the method comprising (a) contacting the contact lens selected from the group consisting of senofilcon a, lotrafilcon a, lotrafilcon b, and comfilcon a b with a lens care solution for a period of at least three hours to minimize the accumulation of tear lipids on the contact lens. The lens care solution comprises 0.5 ppm to 10 ppm α-[4-tris(2-hydroxyethyl)-ammonium chloride-2-butenyl]poly[1-dimethyl ammonium chloride-2-butenyl]-ω-tris(2-hydroxyethyl) ammonium chloride; citrate, citric acid or a mixture thereof; and 0.005 wt.
Bausch & Lomb Incorporated


01/28/16
20160022698 

Method for treating uterine fibroids


The invention relates to a method for treating uterine fibroids, which method comprises administering to a patient in need thereof, an effective amount of 17α-acetoxy-11β-[4-n,n-dimethylamino-phenyl)-19-norpregna-4,9-diene-3,20-dione (ulipristal) or any metabolite thereof. More particularly, the method is useful for reducing or stopping bleeding in a patient afflicted with uterine fibroids, and/or for reducing the size of uterine fibroids..
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services


01/28/16
20160022690 

Combination treatment


The present invention relates to the use of combinations comprising 8-[(1r)-1-(3,5-difluorophenylamino)ethyl]-n,n-dimethyl-2-morpholino-4-oxo-4h-chromene-6-carboxamide or a pharmaceutically acceptable salt thereof and a taxane in the treatment or prophylaxis of cancer; pharmaceutical compositions comprising compound [i] (or a pharmaceutically acceptable salt thereof) and a taxane; kits comprising compound [i] or a pharmaceutically acceptable salt thereof and a taxane, optionally with instructions for use; and methods of treatment comprising the simultaneous, sequential or separate administration of compound [i] or a pharmaceutically acceptable salt thereof and a taxane to warm-blooded animal, such as man.. .
Astrazeneca Ab


01/28/16
20160022676 

Topical medications for bruises and burns


Topical medications to treat the physical effects of bruises and burns. For bruises, the topical medication preferably includes therapeutically effective amounts of vasoconstrictor, such as phenylephrine hcl usp, an anti-inflammatory, such as arica, and compounding agents.
Meridian Research And Development, Inc.


01/28/16
20160022588 

Abuse-proofed oral dosage form


The present invention relates to an abuse-proofed oral dosage form with controlled release of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol for once daily administration, which comprises the active ingredient and/or one or more of the pharmaceutically acceptable salts thereof (a), at least one synthetic or natural polymer (c), delayed-release auxiliary substances, optionally physiologically acceptable auxiliary substances (b) and optionally a wax (d), component (c) or (d) in each case exhibiting a breaking strength of at least 500 n, preferably of at least 1000 n.. .
GrÜnenthal Gmbh


01/28/16
20160021873 

Stem cell preservation medium, stem cell preservation method, and stem cell preservation system


Provided are a stem cell preservation medium, stem cell preservation method and stem cell preservation system which can be used in a slow-freezing method that is used in place of vitrification, have a high cell survival rate and are convenient and highly efficient. The stem cell preservation medium comprises hydroxyethyl starch (hes), dimethyl sulfoxide (dmso), and ethylene glycol (eg).
Riken


01/21/16
20160016881 

Process for the carbonylation of dimethyl ether


A process for preparing methyl acetate by the carbonylation of dimethyl ether with carbon monoxide in the presence of hydrogen and a zeolite catalyst wherein, in a first step the carbonylation is conducted with a carbon monoxide to hydrogen molar ratio of at least 1 and in a second and subsequent step, the carbonylation is conducted with a hydrogen to carbon monoxide molar ratio of greater than 1.. .
Bp Chemicals Limited


01/21/16
20160016878 

Process


A continuous process for the co-production of acetic acid and acetic anhydride by (a) contacting carbon monoxide with a liquid reaction composition comprising methyl acetate, dimethyl ether or a mixture thereof, a group viii metal catalyst, methyl iodide, acetic acid, acetic anhydride, water in a concentration of 0.1 wt % or less, (b) withdrawing liquid reaction composition from the reaction zone and introducing at least a portion of the withdrawn liquid reaction composition into a flash separation zone, and (c) removing from the flash separation zone a vapour fraction comprising acetic anhydride, acetic acid and methyl iodide and a liquid fraction comprising acetic anhydride, and group viii metal catalyst in which at least one of the liquid reaction composition and the withdrawn liquid reaction composition introduced into the flash separation zone comprises at least one metal salt selected from salts of group ia and group iia metals and the molar ratio of acetic acid to acetic anhydride in the vapour fraction removed from the flash separation zone is maintained at greater than or equal to 1, preferably greater than or equal to 1.2.. .
Bp Chemicals Limited


01/21/16
20160016341 

Method for making impact-absorptive material


A method for making an impact-absorptive material is introduced. The method involves mixing silicon dioxide (sio2) particles, polydimethylsiloxane (pdms), and an appropriate amount of an additive, allowing the mixture to settle until tiny bubbles in the mixture are evenly distributed, thereby forming a colloidal solution raw material, adding a crosslinking agent to the colloidal solution raw material to form a colloidal solution plastic material, filling a die with the colloidal solution plastic material, heating the colloidal solution plastic material in the die such that it takes shape and forms an effective impact absorbing material, quickly and at low costs, for use in physical education, medicine, transportation, and safety-enhancing equipment..
National Chung Shan Institute Of Science And Technology


01/21/16
20160016155 

Carbonylation catalyst and process


A catalyst and process for the production of methyl acetate by contacting dimethyl ether and carbon monoxide in the presence of a catalyst which is a zeolite of micropore volume of 0.01 ml/g or less.. .
Bp Chemicals Limited


01/21/16
20160015724 

Novel crystals and process of making 5-(-methyl)-2-methoxy-benzoic acid


The present invention relates to a novel crystals of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid and methods of making the zwitterion of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid.. .
Furiex Pharmaceuticals, Inc.


01/21/16
20160015700 

4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma


The present invention is directed to methods for the treatment of hodgkin's lymphoma comprising administering to a patient in need thereof, a therapeutically effective amount of 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6 -(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide as mono-therapy or as combination or co-therapy with one or more chemotherapeutic agent or chemotherapy regimens.. .
Janssen Pharmaceutica Nv


01/14/16
20160011174 

Assay for determining the cell number in cultured cells


A method for determining the number of cells in an in vitro culture of cells is disclosed, the method comprising culturing cells in the presence of dimethyl sulphoxide (dmso) for a period of time sufficient for the cells to produce dimethyl sulphide (dms), measuring the dms produced by the cultured cells.. .
Keele University


01/14/16
20160011063 

Electronic skin, preparation method and use thereof


The invention provides a piezoresistive electronic skin, a preparation method and a use thereof. The piezoresistive electronic skin uses carbon nanotube film as the conductive layer and uses materials provided with micro-nano patterns, such as polydimethylsiloxane, polyethylene terephthalate, polyvinyl alcohol, polyvinyl formal, polyethylene, and so on, as the substrate, enabling the substrate has advantages of high flexibility and being pliable, and it needs low operating voltage and little power consumption, but has high sensitivity and short response time.
Suzhou Institute Of Nano-tech And Nano-bionics (sinano), Chinese Academy Of Science


01/14/16
20160009764 

Mu opioid receptor agonist analogs of the endomorphins


The invention relates to cyclic peptide agonists that bind to the mu (morphine) opioid receptor and their use in the treatment of acute and/or chronic pain. Embodiments of the invention are directed to cyclic pentapeptide and hexapeptide analogs of endomorphin that have (i) a carboxy-terminal extension with an amidated hydrophilic amino acid and (ii) a substitution in amino acid position 2, and in some embodiments, a 2′,6′-dimethyltyrosine (dmt) residue in place of the n-terminal tyrosine residue a position 1.
The Administrators Of The Tulane Educational Fund


01/14/16
20160009670 

Vortioxetine manufacturing process


A process for the manufacture of vortioxetine is provided in which a compound of formula i, formula i is reacted with optionally substituted piperazine and 2,4-dimethylthiophenol(ate) followed by de-complexation.. .
H. Lundbeck A/s


01/14/16
20160009629 

Carbonylation process


A process for preparing methyl acetate by the carbonylation of dimethyl ether with carbon monoxide in the presence of hydrogen and a zeolite catalyst wherein, in a first step the carbonylation is conducted with a carbon monoxide to hydrogen molar ratio of at least 1 and in a second and subsequent step, the carbonylation is conducted with a hydrogen to carbon monoxide molar ratio of greater than 1.. .
Bp Chemicals Limited


01/14/16
20160009006 

Sheet-shaped mold, production method therefor, and application therefor


Provided is a sheet-shaped mold possessing a high strength and having a low breakage rate in demolding even in a case where the mold is thin and has a large-area. The sheet-shaped mold is prepared by combining a cured silicone rubber containing a polyorganosiloxane and a fiber for reinforcing the cured silicone rubber.
Daicel Corporation


01/14/16
20160008368 

Combination


A novel combination comprising the mek inhibitor n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl; -2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, with a mtor inhibitor, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of mek and/or mtor is beneficial, e.g. Cancer..
Novartis Ag


01/14/16
20160008302 

Compounds and methods for treating aberrant adrenocortical cell disorders


Methods and compositions are provided for treatment of disorders associated with aberrant adrenal cortex cell behavior, including (but not limited to) treatment of adrenocortical carcinoma (acc), cushing's syndrome and/or pituitary acth excess (cushing's disease). Such methods involve administration of an effective amount n-(2,6-bis(1-methylethyl)phenyl)-n′-((1-(4-(dimethylamino)phenyl)cyclopentyl)-methyl)urea hydrochloride to the patient..
Atterocor, Inc.


01/14/16
20160008246 

Sunscreen compositions and methods of their use


Described herein are compositions useful for protecting the skin from the sun. The compositions comprise cosmetic ingredients such as zinc oxide, titanium dioxide, butyloctyl salicylate, and a dermatologically acceptable vehicle.
Mary Kay Inc.


01/14/16
20160008244 

Sunscreen compositions and methods of their use


Described herein are topical skin compositions useful for protecting the skin from the sun. The topical skin compositions comprise cosmetic ingredients such as homosalate; octisalate; oxybenzone; octocrylene; avobenzone; c12-15 alkyl benzoate; dicaprylyl carbonate; glycerin; vp/eicosene copolymer; cetearyl alcohol; caprylyl methicone; ceteth-20 phosphate; silica; and ammonium acryloyldimethyltaurate/vp copolymer.
Mary Kay Inc.


01/07/16
20160006077 

Lithium ion battery


A high-input and high-output battery having a large capacity while guaranteeing safety is provided. As a composition of an electrolytic solution, a composition ratio of ethylene carbonate (ec) is 20 vol % or more and 30 vol % or less, and a composition ratio of dimethyl carbonate (dmc) is 36 vol % or more and 50 vol % or less, and a composition ratio η (dmc/emc) of dimethyl carbonate (dmc) and ethyl methyl carbonate (emc) is 1.0≦η≦1.7.
Shin-kobe Electric Machinery Co., Ltd.


01/07/16
20160002543 

Method for producing non-carcinogenic aromatic process oil


The present invention relates to the chemical or petroleum-processing industry and can be used in the production of petroleum plasticizers for synthetic rubber and tyres. In the method for producing non-carcinogenic aromatic process oil, containing a pca extract of less than 3.0% according to the ip-346 method, said method comprising purifying the oil fractions of petroleum with selective solvents and separating the extract, additionally processing the extract with a polar solvent and producing a raffinate as the end product, the polar solvent used is a mixture of dimethylsulphoxide and nmethylpyrrolidone, which is used for preliminary processing of the extract, wherein, after the preliminary processing, the mixture of extract and polar solvent is filtered, divided and the light phase is sent to the additional processing of the extract with the polar solvent, and the heavy phase is sent to a polar solvent regeneration stage.
Zakrytoe Aktsionernoe Obschestvo "torgovity Dom "orgkhim"


01/07/16
20160002475 

Water-based paint composition for aerosol cans


B) 25 to 45% w/w of a propellant gas component which, based on the propellant gas component, contains at least 75% w/w of dimethyl ether.. .

01/07/16
20160002426 

Additives for improving polyurethane foam performance


A composition and process useful to make flexible polyurethane foams and in particular flexible molded polyurethane foams is disclosed. The usage of dipolar aprotic liquids such as dmso, dmi, sulfolane, n-methyl-acetoacetamide, n,n-dimethylacetoacetamide as well as glycols containing hydroxyl numbers oh#≦1100 as cell opening aides for 2-cyanoacetamide or other similar molecules containing active methylene or methine groups to make a polyurethane foam is also disclosed.
Air Products And Chemicals, Inc.


01/07/16
20160002284 

Process for the preparation of drospirenone


A process is described wherein, by employing 17α-(3-hydroxypropyl) -63,7β3;15β,16β-dimethylene-5β-androstane-3β,5,17β-triol (ii) as starting product, in a single stage reaction there is obtained drospirenone, (i), whereby the reaction is achieved using gaseous oxygen as the stoichiometric oxidant in the presence of a catalytic system containing (i) tempo or a derivative thereof (ii) a ferric salt (fe3+) and (iii) nacl. The product drospirenone is a known synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic action, that is useful for preparing pharmaceutical compositions with contraceptive action..
Industriale Chimica S.r.l.


01/07/16
20160002250 

Polymorphs and salts of a compound


Disclosed are novel crystalline polymorphic forms of 4-(4-(imidazo[1,2-b]pyridazin-2-ylmethoxy)phenyl)-2,2-dimethyl-5-(pyridin-4-yl)furan-3(2h)-one and salts thereof, methods of preparing the crystalline polymorphic forms and salts thereof, pharmaceutical compositions comprising the crystalline polymorphic forms and salts thereof, and methods of treating cns disorders, eating disorders, obesity, compulsive gambling, sexual disorders, narcolepsy, sleep disorders, diabetes, metabolic syndrome, schizophrenia, schizo-affective conditions, huntington's disease, bipolar disorders, dystonic conditions and tardive dyskinesia, or for use in smoking cessation treatment in a patient using the crystalline polymorphic forms and salts thereof.. .
Forum Pharmaceuticals Inc.


01/07/16
20160002194 

1 -(dimethylamino)ethyl-substituted 6h-benzo[c]chromen-6-ones against senile dementia


This invention relates to novel (±)1-(dimethylamino)ethyl substituted 6h-benzo[c]chromen-6-one compounds which are useful as pharmaceutical compositions.. .
Nobel IlaÇ Sanayii Ve Ticaret A.s


01/07/16
20160002158 

Asymmetric synthesis of a substituted pyrrolidine-2-carboxamide


The present invention provides an improved method for the large scale production of the compound 4-{[(2r,3s,4r,5s)-3-(3-chloro-2-fluoro-phenyl)-4-(4-chloro-2-fluoro-phenyl)-4-cyano-5-(2,2-dimethyl-propyl)-pyrrolidine-2-carbonyl]-amino}-3-methoxy-benzoic acid.. .
Hoffmann-la Roche Ag


01/07/16
20160002146 

Method for producing halogen-n,n-dimethylbenzylamines


The invention relates to a method for producing halogen-n,n-dimethylbenzylamines wherein halogen=chlorine or bromine, preferably chloro-n,n-dimethylbenzylamines, preferably ortho-chloro-n,n-dimethylbenzylamine (o-cl-dmba), by reductive amination in the absence of sulfur.. .
Lanxess Deutschland Gmbh


01/07/16
20160002060 

Method for making molecular sieve ssz-98


A method is disclosed for making a new crystalline molecular sieve designated ssz-98. Ssz-98 has the eri framework type and is synthesized using a n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent..
Chevron U.s.a. Inc.


01/07/16
20160002059 

Molecular sieve ssz-98


A new crystalline molecular sieve designated ssz-98 is disclosed. Ssz-98 has the eri framework type and is synthesized using a n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent..
Chevron U.s.a. Inc.


01/07/16
20160001370 

Reducing agents for silver morphology control


A method comprising providing at least one reducing agent comprising at least one phenol group, the at least one reducing agent not also comprising a halogen atom, and reducing at least one silver ion to at least one silver nanowire in a reaction mixture comprising the at least one reducing agent. Exemplary reducing agents are 3,4-dihydroxybenzotriazole, 2,2′-isobutylidene-bis-(4,6-dimethyl-phenol), and tannic acid..
Carestream Health, Inc.


01/07/16
20160001273 

Processes using molecular sieve ssz-98


Uses for a new crystalline molecular sieve designated ssz-98 are disclosed. Ssz-98 has the eri framework type and is synthesized using a n,n′-dimethyl-1,4-diazabicyclo[2.2.2]octane dication as a structure directing agent..
Chevron U.s.a. Inc


01/07/16
20160001059 

Capacitor electrolyte


A capacitor for an implantable medical device is presented. The capacitor includes an anode, a cathode, a separator therebetween, and an electrolyte over the anode, cathode, and separator.
Medtronic, Inc.


01/07/16
20160000922 

Functionalised triblock copolymers and compositions containing such polymers


Amphiphilic triblock copolymers b-a-b, wherein a is a linear poly(ethylene glycol) block, having a number average molecular weight (mn) of between 900 and 3000 daltons, determined with size exclusion chromatography; wherein b are hydrophobic blocks with at least two cyclic monomers selected from the group consisting of glycolide, lactide, 1,3-dioxan-2-one, 5,5-dimethyl-1,3-dioxan-2-one, 1,4-dioxan-2-one, 1,4-dioxepan-2-one, 1,5-dioxepan-2-one, each b-block having a number average molecular weight (mn) of between 400 and 2000 daltons, determined with size exclusion chromatography; and wherein 25% to 100% of the polymer hydroxyl end-groups are covalently modified with at least one derivative of a c2-c20 fatty acid. The invention also relates to compositions with such polymers and the use thereof..
Ingell Technologies Holding B.v.


01/07/16
20160000774 

Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate


This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with dmf. This invention also provides a package comprising laquinimod and dmf for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
Teva Pharmaceutical Industries, Ltd.


12/31/15
20150380273 

Liquid composition used in etching multilayer film containing copper and molybdenum, manufacturing substrate using said liquid composition, and substrate manufactured by said manufacturing method


The present invention provides a liquid composition used for etching a multilayer film containing copper and molybdenum, an etching method for etching a multilayer film containing copper and molybdenum, and a substrate. The present invention further provides a liquid composition for etching a multilayer-film wiring substrate which has an oxide layer (igzo) including indium, gallium and zinc laminated on the substrate, and further a multilayer film including at least a layer containing molybdenum and a layer containing copper provided thereon, a method for etching a multilayer film containing copper and molybdenum from the substrate, and a substrate.
Mitsubishi Gas Chemical Company, Inc.


12/31/15
20150377790 

Apparatus and water testing system


A water testing system having a water sample container that is adapted to retain a water sample, a color indicator container that is adapted to dispense a color indicator which is adapted change the color of the water sample when the water sample contains dtc, and a colorimeter that is adapted to automatically determine a blank value and the concentration of sodium dimethyldithiocarbamate in the water sample. A method for determining the concentration of dtc in a water sample comprising providing a water testing system, placing the water sample in the water sample container, placing the water sample container in the colorimeter, automatically determining a blank value, adding the color indicator to the water sample, placing the water sample container in the colorimeter, and automatically determining the concentration of dtc in the water sample..

12/31/15
20150376390 

Polymer particle, polymer dispersion, producing said polymer dispersion, coating material produced from said polymer dispersion, and coated article


The present invention relates to: a polymer particle in which a urethane resin (a1) and an acrylic polymer (b1) are included in a single particle, said polymer particle having a gel fraction of 10% or more as measured using n,n-dimethylformamide (dmf) as a solvent; a polymer particle in which a urethane resin (a2) having a sulfonic acid group and an acrylic polymer (b2) are included in a single particle, said polymer particle having a surface acid value of 0.1 to 19 mgkoh/g as measured by a potentiometric titration method; and a method for producing a polymer dispersion. According to the present invention, it becomes possible to provide: a polymer dispersion which has excellent polymerization stability and can have an excellent coating viscosity property and excellent storage stability when used in a coating material; a method for producing the polymer dispersion; and a polymer particle contained in the polymer dispersion.
Japan Coating Resin Corporation


12/31/15
20150376361 

Composition for preparing a polymeric foam


The present invention relates to composition for the preparation of a polymeric foam with improved thermal properties, to a polymeric foam obtainable therefrom, and to a method for preparing such a polymeric foam each for them comprising (i) an at least essentially amorphous polymer resin and (ii) a nucleating agent. The at least essentially amorphous polymer resin is preferably polystyrene.
Clariant International, Ltd.


12/31/15
20150376153 

Methods for preparing alkylfurans


Provided herein are methods for preparing alkylfurans, such as 2,5-dialkylfurans and 2-alkylfurans. Furfural or 5-alkylfurfural can be reacted with aniline or diaminobenzene, or derivatives thereof, to form the corresponding imine, which can be reduced to form alkylfurans and to regenerate the aniline or diaminobenzene, or derivatives thereof.
The Regents Of The University Of California


12/31/15
20150376037 

Ion enhancement


A method and apparatus for treating a body of water to kill microorganisms by enhancing the concentration metal ions therein. The apparatus comprising a dispenser with a first housing having a water accessible compartment containing 5,5-dimethylhydantoin for releasing the 5,5-dimethylhydantoin when contacted by the body of water and a second housing having a water accessible compartment containing a biocidal metal to the body of water for generating biocidal metal ions when contacted by the body of water containing the 5,5-dimethylhydantoin.

12/31/15
20150375217 

Dehydration-hydrolysis processes and catalysts therefor


Crystalline zeolites having a fer framework type wherein the crystallites have a dimension in the c-axis of about 500 nanometres (nm) or less, a method for their preparation and a process for the co-production of acetic acid and dimethyl ether comprising the step of contacting methyl acetate and methanol in the presence of catalysts comprising the crystalline zeolites.. .
Bp Chemicals Limited


12/31/15
20150374833 

Polypeptide hydrogel and producing same


A polypeptide hydrogel of the present invention is a hydrogel of a polypeptide derived from spider silk proteins, and has a moisture content of 85.0 to 99.9 mass % based on 100 mass % of the polypeptide hydrogel. A method for producing the hydrogel includes: a solution production step in which a polypeptide derived from spider silk proteins is dissolved in at least one dissolving solvent selected from the group consisting of: (a) dimethyl sulfoxide; (b) dimethyl sulfoxide with an inorganic salt; and (c) n, n-dimethylformamide with an inorganic salt, so as to obtain a solution of the polypeptide; and a substitution step in which the solution produced in the solution production step is substituted with a water-soluble solvent.
Spiber Inc.


12/24/15
20150372620 

Integrated micro/nanogenerator and fabricating the same


The present disclosure discloses an integrated micro/nanogenerator and a method of fabricating the same the integrated micro/nanogenerator has a structure comprising a conducting layer, a pet layer, a pdms layer, a micro-nano hierarchical pdms array and a metal film layer, the conducting layer being manufactured on a surface of the pet layer, the pet layer being made of polyethylene terephthalate; the pdms layer being made of polydimethylsiloxane, and the micro-nano hierarchical pdms array being manufactured on a surface of the pdms layer. The method comprises steps of: 1) fabricating a micro-scale structure on a substrate through a combination of lithography and chemical etching or physical etching; 2) fabricating a nano-scale structure with high density and high depth-to-width ratio directly on a surface of the micro-scale structure through a mask-free optimized deep reactive ion etching process; 3) using a pdms casting film transfer process by adjusting and controlling process parameters, by means of using the mold of mirco-nano hierarchical array structure as a template; 4) fabricating a conducting layer on a surface of the pet layer by using an evaporation or sputtering or chemical vapor deposition process; 5) bonding the pdms layer and the pet layer through high temperature bonding or normal temperature physical pressing; and 6) assembling in sequence and packaging the bonded structure obtained in step 5), the metal film layer, and another bonded structure obtained in step 5)..
Peking University


12/24/15
20150368183 

Manufacturing process for memantine


A method for manufacturing 3,5-dimethyl-1-adamantanamine of the present invention comprises: (i) a step of reacting 3,5-dimethyl-1-adamantanol with an acid and nitrile in an organic solvent to obtain a reaction solution; (ii) a step of adding water to the reaction solution obtained in step (i) to obtain 1-amido-3,5-dimethyladamantane; and (iii) a step of hydrolyzing 1-amido-3,5-dimethyladamantane obtained in step (ii) in the presence of an alcohol-containing solvent and an inorganic base.. .
Mitsubishi Gas Chemical Company, Inc.


12/24/15
20150366877 

Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors


Methods of inhibiting replication of human cytomegalovirus (hcmv) are disclosed. In various configurations, these methods comprise administering a therapeutically effective amount of a bromodomain inhibitor to a subject in need thereof.
Washington University


12/24/15
20150366691 

Materials and methods for improved intragastric balloon devices


Disclosed is a balloon of an intragastric device, comprising, in combination: a core of a first material and having an inner surface and an outer surface; and a coating of a second material on at least one of the inner surface of the core and the outer surface of the core. Disclosed is a method, comprising, in combination: creating a core of a balloon by a core in a first material; dipping at least one of an inner surface of the core and an outer surface of the core in a second material, whereby a coating is formed on at least one of the inner surface of the core and the outer surface of the core.
Reshape Medical, Inc.


12/24/15
20150366210 

Composition for detection and treatment of bed bugs


The present disclosure provides for a composition and method for attracting bed bugs to a trap or to a location where an insecticide or pesticide is present, or to a trap or a location where a bed bug infestation can be detected. The present disclosure provides for a composition for attracting bed bugs that includes one or more of methyl diethanolamine (mdea), monoethanolamine (mea), diethanolamine (dea), triethanolamine (tea), and dimethyl trisulfide (dmts); a carrier; and optionally one or more amides selected from oleamide, octanamide, nonanamide, and laurylamide; urea, biuret, or triuret; and one or more aliphatic fatty acids.
Regents Of The University Of Minnesota


12/17/15
20150364796 

Low temperature electrolyte for high capacity lithium based batteries


Electrolytes for lithium based batteries are described with good temperature tolerance over appropriate temperature ranges for uses in vehicles. In particular, the electrolytes are suitable for high voltage operation over 4.4v and can provide high rate performance.
Envia Systems, Inc.


12/17/15
20150362847 

Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus


The present invention can provide an electrophotographic photosensitive member that is capable of suppressing potential variation as much as possible to allow a high-quality image to be output, as well as a process cartridge and an electrophotographic apparatus including the electrophotographic photosensitive member. Therefore, the electrophotographic photosensitive member of the present invention is an electrophotographic photosensitive member comprising: a support; a charge-generating layer; and a charge-transporting layer on the charge-generating layer, in which the charge-generating layer comprises a gallium phthalocyanine crystal in which a polar solvent is contained, and the polar solvent is at least one selected from dimethylsulfoxide, n,n-dimethylformamide, n-methylformamide, n-propylformamide, n-vinylformamide and n-methylpyrrolidone relative to gallium phthalocyanine, and the content of the polar solvent is 0.1% by mass or more and 2.0% by mass or less based on a gallium phthalocyanine in the gallium phthalocyanine crystal, and the charge-transporting layer contains a compound represented by formula (1)..
Canon Kabushiki Kaisha


12/17/15
20150361197 

Initiation of controlled radical polymerization from lactide monomer


A lactide-functionalized polymer is synthesized by polymerizing a monomer capable of undergoing radical polymerization (e.g., styrenic, vinylic, acrylic, etc.) using a brominated lactide initiator via atom transfer radical polymerization (atrp). In some embodiments of the present invention, the brominated lactide initiator is 3-bromo-3,6-dimethyl-1,4-dioxane-2,5-dione prepared by reacting lactide with n-bromosuccinimide in the presence of benzoyl peroxide..
International Business Machines Corporation


12/17/15
20150360409 

Flexible porous film


This invention provides a method for fabricating a flexible porous film. One application of the film is for fabricating a flexible lithium-ion battery.
Nano And Advanced Materials Institute Limited


12/17/15
20150360211 

Process for treating zeolite catalysts


A process for treating a zeolite catalyst for the carbonylation of dimethyl ether to produce methyl acetate in which the catalyst is contacted with a treatment gas comprising water vapour in an amount of at least 1 mol % and at a temperature below which dealumination of the zeolite structure occurs.. .
Bp Chemicals Limited


12/17/15
20150359818 

Method for producing a gas transporting rheological medium


A method for producing a gas transporting rheological medium, said method comprises: (a) hydrating and dispersing a thickening agent in a fluid medium; (b) adding a first gas for dissolution and/or adsorption the fluid medium using a minimum fluid system pressure of about 7 psig; (c) mechanically emulsifying dimethylpolysiloxane into the fluid medium; (d) adding a source of one or more +2 valence cations to the suspension for 10 crosslinking to form a gel; and (e) dispensing the gel into a container.. .

12/17/15
20150359768 

Composition and compounded therapy


A compounded transdermal cream for the topical administration of a compounded therapy includes a first active agent selected from the group consisting of nabumetone in an amount between approximately 5.0% and approximately 25% by weight of the transdermal cream and amitriptyline in an amount between approximately 0.5% and approximately 4.0% by weight of the transdermal cream; a second active agent comprising a nerve depressant in an amount between approximately 5.0% and 15.0% by weight of the transdermal cream, wherein the nerve depressant is gabapentin; a third active agent comprising a local anesthetic in an amount between approximately 1.0% and approximately 7.0% by weight of the transdermal cream, wherein the local anesthetic comprises lidocaine and prilocaine; and dimethyl sulfoxide (dmso).. .
Cmpd Licensing, Llc


12/17/15
20150359767 

Composition and compounded therapy


A compounded transdermal cream for topical administration of a compounded therapy includes a nerve depressant such as gabapentin in an amount between approximately 5% and 15% by weight of the transdermal cream, an nsaid (non-steroidal anti-inflammatory drug) such as nabumetone in an amount between approximately 5% and approximately 25% by weight of the transdermal cream, a tricyclic antidepressant such as amitriptyline in an amount between approximately 0.5% and approximately 4% by weight of the transdermal cream, a local anesthetic such as lidocaine and prilocaine in an amount between approximately 1% and approximately 7% by weight of the transdermal cream, and dimethyl sulfoxide (dmso).. .
Cmpd Licensing, Llc


12/10/15
20150357534 

Atomic layer deposition (ald) of tio2 using (tetrakis(dimethylamino)titanium) tdmat as an encapsulation and/or barrier layer for ald pbs


A method of encapsulating pbs quantum dots is provided that includes depositing, using atomic layer deposition (ald), a first layer of tio2 on a substrate, depositing, using ald, a first layer of pbs quantum dots on the first layer of tio2, and depositing, using ald, an encapsulating layer of the tio2 on the first layer of tio2 and the first layer of pbs quantum dots, where the first layer of pbs quantum dots are encapsulated and separated by the first layer of tio2 and the encapsulating layer of tio2.. .
Honda Patents & Technologies North America, Llc


12/10/15
20150357261 

Heat conductive silicone composition, heat conductive layer, and semiconductor device


Provided is a heat conductive silicone composition disposed between a heat generating electronic component and a member for dispersing heat, wherein the heat conductive silicone composition contains (a) an organopolysiloxane having at least two alkenyl groups in one molecule and having a dynamic viscosity at 25° c. Of 10 to 100,000 mm2/s, (b) a hydrolyzable dimethylpolysiloxane having three functional groups at one end expressed by formula (1), (c) a heat conductive filler having a heat conductivity of 10 w/m° c.
Shin-etsu Chemical Co., Ltd.


12/10/15
20150353672 

Rigid foam


A rigid foam having increased flame retardance comprises the reaction product of an isocyanate component and an isocyanate-reactive component. The isocyanate component and an isocyanate-reactive component are reacted in the presence of an isocyanurate catalyst component and a carbodiimide catalyst component.
Basf Se


12/10/15
20150353577 

Method for producing (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one


It is an object of the present invention to provide a method for efficiently producing (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one (1), which is important as an intermediate compound for the production of an fxa-inhibiting compound. A method for producing (1s,4s,5s)-4-bromo-6-oxabicyclo[3.2.1]octan-7-one (1), which comprises treating an (r)-α-phenylethylamine salt of (s)-3-cyclohexene-1-carboxylic acid with 1,3-dibromo-5,5-dimethylhydantoin or n-bromosuccinimide in a solvent..
Daiichi Sankyo Company, Limited


12/10/15
20150353520 

Salts and crystal forms


This invention relates to salts and crystal forms of (s)-6-chloro-7-(1,1-dimethylethyl)-2-trifluoromethyl-2h-1-benzopyran-3-carboxylic acid, compound a, which is cyclooxygenase-2 inhibitor. The present invention provides a salt of compound a, a crystal form thereof, a process for preparing the said salt and a pharmaceutical composition thereof and its use.
Askat Inc.


12/10/15
20150352535 

Catalyst and process for the production of acetic acid and dimethyl ether


A process for the co-production of acetic acid and dimethyl ether products from a mixture of methanol and methyl acetate by contacting the mixture at a temperature from 200 to 260° c., with a catalyst composition comprising a zeolite possessing a 2-dimensional channel system comprising at least one channel having a 10-membered ring and a silica:alumina molar ratio of at least 22:1.. .
Bp Chemicals Limited


12/10/15
20150352502 

Method for manufacturing sulfone polymer membrane


The invention pertains to a method for manufacturing a sulfone polymer membrane comprising the steps of: (i) preparing a sulfone polymer solution [solution (sp)] comprising: —at least one sulfone polymer [polymer (p)]; a solvent mixture [mixture (m)] comprising: at least one solvent selected from the group consisting of diesters of formula (ide) and ester-amide of formula (lea), and optionally comprising at least one diamide of formula (ida): r1—ooc-ade-coo—r2 (lde); r1—ooc-aeaco—nr3r4 (lea); r5r6n—oc-ada-co—nr5r6 (lda), wherein: r1 and r2, equal to or different from each other, are independently selected from the group consisting of c1-c20 hydrocarbon groups; r3, r4, r5 and r6 equal to or different from each other and at each occurrence, are independently selected from the group consisting of hydrogen, c1-c36 hydrocarbon groups, possibly substituted, being understood that r3 and r4 might be part of a cyclic moiety including the nitrogen atom to which they are bound, said cyclic moiety being possibly substituted and/or possibly comprising one or more than one additional heteroatom, and mixtures thereof; ade, aea, and ada equal to or different from each other, are independently a linear or branched divalent alkylene group, and optionally dimethylsulfoxide (dmso); (ii) processing said solution (sp) into a film; (iii) immersing said film in a non-solvent bath.. .
Solvay Sa


12/10/15
20150352320 

Catheters having an antimicrobial treatment


A vascular access product is provided having a component with a plurality of external surfaces. At least one of the surfaces is coated with an antimicrobial treatment, wherein the antimicrobial material comprises a silane quaternary ammonium salt.
Parasol Medical Llc


12/10/15
20150352121 

Combination


A novel combination comprising the pi3k-β inhibitor 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1h-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, with a b-raf inhibitor, particularly n-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of pi3k-β and/or b-raf is beneficial, eg. Cancer..
Glaxosmithkline Llc


12/10/15
20150352117 

Combination


The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2h-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7-tetrahydro-2h-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof..
Novartis Ag


12/10/15
20150352065 

Methods of treatment of fibrosis and cancers


The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethyl-methyloxyphenyl]prop-2-en-1-one for treating fibrotic diseases and cancers.. .
Genfit




Dimethyl topics: Physiologic, Hydrochloric Acid, Fresnel Zone, Aberration, Ophthalmic, Liquid Crystal, Imaging System, Pharmaceutically Acceptable Salt, Pharmaceutically Acceptable Salts, Chloric Acid, Tartaric Acid, Fumaric Acid, Antagonist, Bradykinin, Enantiomer

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Dimethyl for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dimethyl with additional patents listed. Browse our RSS directory or Search for other possible listings.


2.237

4561

3 - 0 - 101